Blood MRNA Expression of REV3L and TYMS As Potential Predictive Biomarkers from Platinum-based Chemotherapy Plus Pemetrexed in Non-small Cell Lung Cancer Patients

Overview

Journal Cancer Chemother Pharmacol

Specialty Oncology

Date 2019 Dec 14

PMID 31832811

Citations 12

Authors

M Teresa Agullo-Ortuno

Inmaculada Garcia-Ruiz

C Vanesa Diaz-Garcia

Ana B Enguita

Virginia Pardo-Marques

Elena Prieto-Garcia

Santiago Ponce

Lara Iglesias

Jon Zugazagoitia

Jose A Lopez-Martin

Luis Paz-Ares

Juan A Nunez

Affiliations

Soon will be listed here.

Abstract

Purpose: Therapeutic options for cancer patients have increased in the last years, although drugs resistance problem remains unresolved. Genetic background in individual susceptibility to cancer treatment could influence the therapy responses. The aim of this study was to explore the feasibility of using blood 4 genes (AEG-1, BRCA-1, REV3L and TYMS) expression levels as a predictor of the efficacy of pemetrexed therapy in patients with advanced non-small cell lung cancer.

Methods: Sixteen patients from the Medical Oncology Department at "12 de Octubre" Hospital, were included in the study. Total mRNA was isolated from blood samples, and gene expression was analyzed by RT-qPCR. A panel of lung tumor cell lines were used in cell proliferation tests and siRNA-mediated silencing assays.

Results: Similarity between blood gene expression levels and protein expression in matched tumor tissue was observed in 54.54% (REV3L) and 81.81% (TYMS) of cases. Gene expression of REV3L and TYMS in blood correlated directly and inversely, respectively, with progression-free survival and overall survival in the patients from our cohort. In tumor cell lines, the knockdown of REV3L conferred resistance to pemetrexed treatment, and the TYMS silencing increased the pemetrexed sensitivity of tumor cells.

Conclusions: The use of peripheral blood samples for expression quantification of interest genes is an affordable method with promising results in the evaluation of response to pemetrexed treatment. Therefore, expression levels of REV3L and TYMS genes might be used as predictive biomarkers in advanced NSCLC patients.

Citing Articles

Unveiling the oncogenic significance of thymidylate synthase in human cancers.

Geng Y, Xie L, Wang Y, Wang Y Am J Transl Res. 2024; 16(10):5228-5247.

PMID: 39544745 PMC: 11558401. DOI: 10.62347/IRUZ1011.

Identifying lncRNAs and mRNAs related to survival of NSCLC based on bioinformatic analysis and machine learning.

Yue W, Wang J, Lin B, Fu Y Aging (Albany NY). 2024; 16(9):7799-7817.

PMID: 38696317 PMC: 11131976. DOI: 10.18632/aging.205783.

Exploring effective biomarkers and potential immune related gene in small cell lung cancer.

Yunchu Y, Miyanaga A, Matsuda K, Kamio K, Seike M Sci Rep. 2024; 14(1):7604.

PMID: 38556560 PMC: 10982305. DOI: 10.1038/s41598-024-58454-4.

SP3-induced Timeless transcription contributes to cell growth of lung adenocarcinoma cells.

Tian P, Du D, Yang L, Zhou N, Tao L PLoS One. 2024; 19(2):e0298295.

PMID: 38354174 PMC: 10866488. DOI: 10.1371/journal.pone.0298295.

Evolutionary Analysis of TCGA Data Using Over- and Under- Mutated Genes Identify Key Molecular Pathways and Cellular Functions in Lung Cancer Subtypes.

Freischel A, Teer J, Luddy K, Cunningham J, Artzy-Randrup Y, Epstein T Cancers (Basel). 2023; 15(1).

PMID: 36612014 PMC: 9817988. DOI: 10.3390/cancers15010018.

References

Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

Novello S, Barlesi F, Califano R, Cufer T, Ekman S, Giaj Levra M . Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(suppl 5):v1-v27. DOI: 10.1093/annonc/mdw326. View

Rosell R, Molina M, Serrano M . EGFR mutations in circulating tumour DNA. Lancet Oncol. 2012; 13(10):971-3. DOI: 10.1016/S1470-2045(12)70369-8. View

Yang J, Hirsh V, Schuler M, Yamamoto N, OByrne K, Mok T . Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27):3342-50. DOI: 10.1200/JCO.2012.46.1764. View

Hata M, Koike I, Wada H, Miyagi E, Kasuya T, Kaizu H . Radiation therapy for extramammary Paget's disease: treatment outcomes and prognostic factors. Ann Oncol. 2013; 25(1):291-7. DOI: 10.1093/annonc/mdt478. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Lee L, Yu J, Lo Y, Chen Y, Wang D, Cho C . Energy types of snoring sounds in patients with obstructive sleep apnea syndrome: a preliminary observation. PLoS One. 2013; 7(12):e53481. PMC: 3534069. DOI: 10.1371/journal.pone.0053481. View

Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol J, Bidoli P . Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3,.... Lancet Oncol. 2012; 13(3):247-55. DOI: 10.1016/S1470-2045(12)70063-3. View

10.

Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol J, Bidoli P . PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013; 31(23):2895-902. DOI: 10.1200/JCO.2012.47.1102. View

11.

Shih C, Chen V, Gossett L, Gates S, MacKellar W, Habeck L . LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997; 57(6):1116-23. View

12.

Buque A, Aresti U, Calvo B, Sh Muhialdin J, Munoz A, Carrera S . Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells. PLoS One. 2013; 8(5):e63338. PMC: 3652812. DOI: 10.1371/journal.pone.0063338. View

13.

Chattopadhyay S, Moran R, Goldman I . Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther. 2007; 6(2):404-17. DOI: 10.1158/1535-7163.MCT-06-0343. View

14.

Song L, Li W, Zhang H, Liao W, Dai T, Yu C . Over-expression of AEG-1 significantly associates with tumour aggressiveness and poor prognosis in human non-small cell lung cancer. J Pathol. 2009; 219(3):317-26. DOI: 10.1002/path.2595. View

15.

Yoo B, Chen D, Su Z, Gredler R, Yoo J, Shah K . Molecular mechanism of chemoresistance by astrocyte elevated gene-1. Cancer Res. 2010; 70(8):3249-58. PMC: 2855753. DOI: 10.1158/0008-5472.CAN-09-4009. View

16.

Emdad L, Das S, Dasgupta S, Hu B, Sarkar D, Fisher P . AEG-1/MTDH/LYRIC: signaling pathways, downstream genes, interacting proteins, and regulation of tumor angiogenesis. Adv Cancer Res. 2013; 120:75-111. PMC: 3928810. DOI: 10.1016/B978-0-12-401676-7.00003-6. View

17.

Bonanno L, Costa C, Majem M, Favaretto A, Rugge M, Rosell R . The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy. Ann Oncol. 2013; 24(4):1130-2. DOI: 10.1093/annonc/mdt063. View

18.

Shen J, Wei J, Guan W, Wang H, Ding Y, Qian X . Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer. J Transl Med. 2014; 12:355. PMC: 4302091. DOI: 10.1186/s12967-014-0355-2. View

19.

Kumarswamy R, Mudduluru G, Ceppi P, Muppala S, Kozlowski M, Niklinski J . MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer. 2011; 130(9):2044-53. DOI: 10.1002/ijc.26218. View

20.

Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A . Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006; 107(7):1589-96. DOI: 10.1002/cncr.22208. View

21.

Sullivan E, Kurtoglu M, Brenneman R, Liu H, Lampidis T . Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Cancer Chemother Pharmacol. 2013; 73(2):417-27. DOI: 10.1007/s00280-013-2366-8. View